Compare ALGS & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALGS | GRF |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 39.9M |
| IPO Year | 2020 | N/A |
| Metric | ALGS | GRF |
|---|---|---|
| Price | $5.68 | $10.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 48.7K | 4.0K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ N/A | $8.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $9.60 |
| 52 Week High | $13.69 | $11.85 |
| Indicator | ALGS | GRF |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.88 |
| Support Level | N/A | $9.69 |
| Resistance Level | N/A | $10.64 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 53.61 |
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.